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We describe a reference panel of 64,976 human haplotypes at 
39,235,157 SNPs constructed using whole genome sequence data from 20 
studies of predominantly European ancestry. Using this resource leads to 
accurate genotype imputation at minor allele frequencies as low as 0.1%, a 
large increase in the number of SNPs tested in association studies and can 
help to discover and refine causal loci. We describe remote server 
resources that allow researchers to carry out imputation and phasing 
consistently and efficiently.  
 
Over the last decade, large scale international collaborative efforts have created 
successively larger and more ethnically diverse genetic variation resources. For 
example, in 2007 the International HapMap Project produced a haplotype 
reference panel of 420 haplotypes at 3.1M SNPs in 3 continental populations
1
. 
More recently, the 1000 Genomes Project has produced a series of datasets built 
using low-coverage whole genome sequencing (WGS), culminating in 2015 in a 
reference panel (1000GP3) of 5,008 haplotypes at over 88M variants from 26 
world-wide populations
2
. In addition, several other projects have collected low-
coverage WGS data in large numbers of samples that could potentially also be 
used to build haplotype reference panels
3-5
. A major use of these resources has 
been to facilitate imputation of unobserved genotypes into genome-wide 
association study (GWAS) samples that have been assayed using relatively 
sparse genome-wide microarray chips. As the reference panels have increased in 
number of haplotypes, SNPs and populations, genotype imputation accuracy has 
increased, allowing researchers to impute and test SNPs for association at ever 
lower minor allele frequencies. A succession of methods developments have 
provided researchers with the tools to cope with these increasing larger panels 
6-
11
. 
 
We formed the Haplotype Reference Consortium (HRC) (see URLs) to bring 
together as many WGS datasets as possible to build a much larger combined 
haplotype reference panel. By doing so, our aim is to provide a single centralized 
resource for human genetics researchers to carry out genotype imputation. Here 
we describe the first HRC reference panel that combines datasets from 20 
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different studies (Supplementary Table 1). The majority of these studies have 
low-coverage WGS data (4-8X coverage) and are known to consist of samples 
with predominantly European ancestry. However the 1000 Genomes Phase 3 
cohort, which has diverse ancestry, is also included. This reference panel consists 
of 64,976 haplotypes at 39,235,157 SNPs that have evidence of having a minor 
allele count (MAC) greater or equal to 5. 
 
We took the following approach to create the reference panel. We combined 
existing sets of genotype calls from each study to determine a ‘union’ set of 
95,855,206 SNP sites with MAC >= 2.  After initial tests, we decided for this first 
version of the HRC panel not to include small insertions and deletions (indels), 
since these were very inconsistently called across projects. We then used a 
standard tool to calculate the genotype likelihoods consistently for each sample 
at each site from the original study BAM files (see Methods) and make a baseline 
set of non-LD based genotype calls. We next applied a number of filters to 
remove poor quality sites (see Methods). We restricted this site list to sites with 
MAC >= 5 based on the calls made originally by the individual studies, 
corresponding to a minimum minor allele frequency (MAF) of 0.0077%, then 
added back sites that are present on several commonly used SNP microarray 
chips in GWAS. Sites with lower MAF would be likely to be poorly imputed. This 
site list consisting of 44,187,567 sites exhibited improved quality compared to 
the unfiltered MAC >= 5 site list when assessed by measuring a per sample 
transition-to-transversion (Ts/Tv) ratio (Supplementary Figures 1-2). We also 
detected and removed 301 duplicate samples across the whole dataset (see 
Methods). 
 
Calling genotypes and phasing using low-coverage WGS data has been a 
computational challenging step for many of the 20 studies providing data. To 
reduce computation, we carried out this step on genotype likelihoods from all 
32,611 samples together, and leveraged the original separately called haplotypes 
from each study to help reduce the search space of the calling algorithm (see 
Methods). We then applied a further refinement step by re-phasing the called 
genotypes using the SHAPEIT3 method
12
, based on experience from the UK10K 
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project, which found this re-phasing approach produced substantially improved 
imputation accuracy when using the haplotypes
4
. After final genotype calling, we 
removed a further 123 samples (see Methods) and filtered out 4,952,410 sites 
whose MAC after refinement and sample removal was below 5, resulting in a 
final set of 39,235,157 sites and 32,488 samples.  By measuring genotype 
discordance of the called genotypes compared to Illumina OMNI2.5M chip 
genotypes available on the 1000 Genomes samples we showed that both our site 
filtering strategy and the increased sample size of HRC led to improved accuracy 
(Supplementary Table 2). For example, we obtained a non-reference allele 
discordance of 0.39% on the full HRC dataset with site filtering, compared to 
0.67% on the subset of 1000GP3 samples. 
 
We next carried out experiments to assess and illustrate the downstream 
imputation performance compared to previous haplotype reference panels. To 
mimic a typical imputation analysis, we created a pseudo-GWAS dataset using 
high-coverage Complete Genomics (CG) WGS genotypes on 10 CEU samples (see 
URLs). We extracted the CG SNP genotypes at all the sites included on an 
Illumina 1M SNP array (Human1M-Duo v3C). These were used to impute the 
remaining genotypes which were then compared to the held out genotypes, 
stratifying results by MAF of the imputed sites. Figure 1 shows that the HRC 
reference panel leads to a large increase in imputation performance when using 
a 1M SNP chip, compared to the 1000GP3 (R
2
=0.64 vs R
2
=0.36 at MAF = 0.1%) 
and also that the re-phasing step using SHAPEIT3 is worthwhile.  HRC 
imputation at 0.1% frequency provides similar accuracy to 1000GP3 imputation 
at 0.6% frequency. Supplementary Figures 3 and 4 show the results from a 
denser (Illumina OMNI 5M) SNP chip and a sparser (Illumina Core Exome). 
To illustrate the benefits of using the HRC resource, we imputed a GWAS study of 
1,210 samples from the InCHIANTI study
13
, including 534 that did not contribute 
to the HRC reference panel because they were not sequenced. Imputing using the 
HRC panel resulted in 15,501,516 SNPs passing an imputation quality threshold 
of r
2
≥0.5 compared to 13,238,968 variants (11,908,509 SNPs and 1,330,459 
indels) when imputing using 1000 Genomes Phase 3, an increase of over 2 
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million variants. Taking the intersection of variant sites between the two panels 
to account for the filtering applied to the HRC panel resulted in 13,364,795 SNPs 
and 10,728,322 SNPs with r
2
≥0.5 for HRC and 1000 Genomes Phase 3 panel, 
respectively. The majority of these additional SNPs occur at the lower frequency 
range (Supplementary Table 3).  
 
We next tested the HRC imputed genotypes for association with 93 circulating blood 
marker phenotypes, including many of relevance to human health such as lipids, 
vitamins, ions, inflammatory markers and adipokines
14,15
.This analysis highlighted 
potential novel associations at the nominal GWAS significance threshold of 5e-8 
(Supplementary Table 4). When we repeated the imputation using the HRC panel 
without the overlapping InCHIANTI samples, we obtained similar results 
(Supplementary Table 4). We took these SNPs forward for replication in the SHIP 
and SHIP-TREND cohorts (see Methods) and found that two of the SNPs replicated 
(Supplementary Table 5). Specifically, we found that SNP rs150956780 (MAF= 0.6%) 
was associated with the Lactic Dehydrogenase phenotype (meta-analysis p-value = 
3.779E-29) and SNP rs147142246 (MAF= 0.6%) was associated with the Potassium 
phenotype (meta-analysis p-value = 8.7E-09). We also found that it is possible for 
HRC imputation to refine signals of association. For example, Figure 2 shows the 
association results of HapMap2, 1000GP3 and HRC based imputation for the α
1
-
antitripsin phenotype at the SERPINA1 locus. HRC imputation gives a clear 
refinement of the signal at the rare causal SNP rs28929474 (MAF=0.5%) 
(Supplementary Table 6), known to predispose to the alpha 1 antitrypsin 
deficiency lung condition emphysema 
16,17
. Similar results were obtained when 
using the HRC panel that excluded the InCHIANTI samples  (data not shown). 
 
Since the HRC reference panel combines data from many different studies with a 
range of restrictions on data release we have developed centralized imputation 
server resources (see URLs). Under this model researchers upload phased or 
unphased genotype data and imputation is carried out on central servers. Once 
completed researchers can download imputed datasets. Along similar lines, we 
have also developed a lower throughput phasing server for haplotype estimation 
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of clinical samples with genotypes from high-coverage WGS data that takes 
advantage of rare variant sharing 
18
 (see URLs). A limited subset of HRC 
haplotypes will be made available for researchers via the European Genome-
phenome Archive (EGA) for the sole purpose of phasing and imputation. 
 
This first release of the HRC is the largest human genetic variation resource to 
date and has been created via an unprecedented collaboration of data sharing 
across many groups. We envisage continuing to expand the HRC and are 
currently planning a second HRC release differing from the first release in two 
ways. Firstly, we aim to substantially increase the ethnic diversity of the panel, 
by including data from sequencing studies in world-wide sample sets such as the 
CONVERGE study
19
, AGVP
20
 and HGDP
21
  Secondly, we aim to include short 
insertions and deletions in addition to SNP variants.  In the limit of a reference 
panel consisting of the whole human population except the person being 
imputed, then imputation would likely be almost perfect for alleles at any 
frequency, since the panel would contain close relatives that share long and 
almost identical tracts of sequence. Therefore, we do expect to be able to make 
future gains in imputation performance. In some populations that have 
experienced isolation (like Sardinia or Iceland) we expect to approach this limit 
much faster. Thinking further ahead, we hope to work closely with efforts under 
way to collect large samples of high-coverage sequenced samples such as the UK 
100,000 Genomes Project (see URLs). 
 
Online methods 
 
Union site list  
Every study provided us with their most recent version of their haplotypes in 
VCF format with one VCF for every autosome. For every cohort, bcftools (v0.2.0-
rc12) was used to create an entire-autosome, SNP-only site list with alternate 
and total allele count information from these per-chromosome haplotypes. 
Multiallelic SNPs were broken into biallelics using ‘bcftools norm’. These per-
cohort site lists were merged into a single file using an in-house Perl script that 
correctly merges alternate and total allele counts. We created site lists called 
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MAC2 and MAC5 containing only sites with a minor allele count (MAC) across all 
studies of >= 2 and >=5, respectively, using bcftools. These sites lists contained 
95,855,206 and 51,060,347 sites, respectively. 
 
Genotype likelihood calculations 
The 'samtools mpileup' command was used to generate genotype likelihoods 
(GLs) at all MAC2 sites on a per sample basis from each sample’s BAM file. The 
pipeline and software versions have been made available online (see URLs). The 
resulting BCF files were merged using the 'bcftools merge' command and the 
MAC2 sites and alleles extracted using the 'bcftools call' command. The use of 
'bcftools call' here made a baseline set of non-LD based genotype calls for each 
site across all samples. These calls were used for some initial sample QC (see 
Sample filtering section). We calculated GLs on 33,070 samples in total. 
 
Site filtering 
We used an ad-hoc method for initial variant filtering which enabled us to 
identify variants that had been filtered out ‘quite often’ by our submitting 
studies. For each site and for each cohort, we labelled the site as “called” in that 
study if the putative calls from bcftools based on GLs exhibited more than one 
allele in that cohort, or “not called” if it showed no variation. We also used the 
haplotype sets provided by each study to determine whether each study had 
filtered out each site or not using their own internal calling pipeline. To 
determine a threshold of “number of times filtered out”, we stratified the sites  
according to their called status versus their filtered status (Supplementary 
Figure 5). We also measured the Ts/Tv ratio of the set of SNPs for each of these 
stratified combinations. SNPs corresponding to the cells above the red line in the 
figure were filtered out, removing all cells which had been filtered out by more 
than 4 studies or have Ts/Tv ratio less than 1.7.  
 
We also applied a set of additional site filters as follows. We filtered out sites not 
on the MAC5 site list to restrict the site list to those that could be imputed well. 
We also filtered out sites if (i) any study (apart from 1000 Genomes) had a 
Hardy-Weinberg Equilibrium (HWE) p-value < 10
-10
, (ii) any study (apart from 
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1000 Genomes) had an overall inbreeding coefficient < -0.1, (iii) a MAF>0.1 with 
the site being called in fewer than 3 of the studies and not called in 1000 
Genomes (the latter restriction kept sites present at high frequencies in non-
European populations that were only called in 1000 Genomes).  We also filtered 
out sites called only in the GoNLstudy or IBD cohort. We completely excluded 
GPC haplotypes from this step of the site list creation process.  
 
After applying these filters, the site list comprised of 44,038,997 sites. Finally, we 
made sure that 4,914,335 sites found on a selection of common SNP genotyping 
arrays and those used in the GIANT consortium and the Global Lipids 
Consortium (Supplementary Table 7) were included in the final site list.  The 
final site list after this filtering contained 44,187,567 sites. 
 
Sample filtering 
Having used 'bcftools call' to extract sites and alleles, we had a set of baseline 
non-LD genotype calls (see Genotype likelihood calculations section). Based on 
these calls for chromosome 22, some outlier samples were evident and we 
removed 150 samples showing evidence for fewer than 10,000 non-reference 
SNPs or more than 10 singletons across the chromosome. This left a total of 
32,920 samples. 
 
To detect possible duplicates we used the original genotype calls submitted by 
the individual studies. We selected 1000 random sites that (1) were biallelic; (2) 
had European minor allele frequency > 5% in 1000GP3; and (3) had no missing 
data in any of the individual studies. Using the 'bcftools gtcheck' command, we 
counted the number of genotypes that differed between each sample pair. There 
was a clear set of 269 sample pairs with very few genotypes differing over the 
1000 sites. We identified these samples as duplicates either within or between 
studies and removed one of the samples in the pair as described in 
Supplementary Table 8. Due to some samples being represented more than 
twice, there were a total of 261 samples removed due to duplicates. Before 
genotype calling, we also removed (i) 9 samples for which we had Complete 
Genomics data so that we could use these samples for testing purposes, (ii) 31 
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samples from 1000GP3 that were related samples (see URLs), (iii) 8 samples 
from the HELIC, AMD and ProjectMinE studies with sample labeling 
inconsistencies. These filters resulted in 32,611 samples being used for the 
genotype calling and phasing steps. 
 
In addition, after the phasing, 83 samples from the AMD study were removed as 
the consent for these samples had been removed.  We also repeated the 
duplicate detection process on the final HRC genotype calls, since some studies 
increased in size late on within the analysis process. This resulted in an extra 40 
samples being removed and a total of 32,488 samples in the final phased 
reference panel. 
 
Genotype calling method leveraging existing haplotype calls 
We called genotypes from the genotype likelihoods computed on the HRC 
samples by extending the SNPTools
22
 algorithm to leverage pre-existing 
haplotypes available from each cohort. Like other phasing and calling 
approaches
8,10
, SNPTools is an MCMC approach in which each sample's 
haplotypes and genotypes are iteratively updated using the current estimates of 
all other samples. A low-complexity Hidden Markov Model (HMM) with just four 
states is used to update each sample, where the states are a set of four "surrogate 
parent" haplotypes. The MCMC sampler employs a Metropolis-Hastings (MH) 
step to sample the set of surrogate parents. In large sample sizes the search 
space for these surrogate haplotypes is huge and results in low acceptance rates 
for the sampler. Our extension, called GLPhase (see URLs) uses pre-existing 
haplotypes to restrict the set of possible haplotypes from which the MH sampler 
may choose surrogate parent haplotypes. For each individual, we restrict the 
search space to 200 haplotypes that most closely match the two pre-existing 
haplotypes of the individual using a Hamming distance metric (100 for each 
haplotype). We run the method on chunks of 1,024 sites at a time, which is the 
default setting for SNPtools. Since the pre-existing haplotypes from each study 
do not contain exactly the same set of sites we filled in missing alleles in the pre-
existing haplotypes at our site list using the major allele at each site. 
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Restricting the search space in this way allows us to reduce the number of burn-
in iterations from 56 to 5, the number of sampling iterations from 200 to 95, and 
the number of MH steps taken at each iteration for each individual from 2N to 
100, where N is the number of samples being phased. This reduces the 
complexity of our phasing algorithm from O(N
2
) to O(N). Although our 
implementation of the Hamming distance search has complexity O(N
2
), for N = 
30,000, the impact of the search on run time is small (~5% of run time on each 
chunk). A chunk of 1024 sites can be phased in ~200 minutes using ~1.3GB of 
RAM. Once sample sizes are encountered where the Hamming distance search 
begins to dominate, our implementation could be replaced with O(N log N) 
clustering algorithms that we have implemented within the SHAPEIT3 
algorithm
12
.  
 
To illustrate how important GLPhase was to genotype calling and phasing on 
such a large sample size, we carried out a comparison to Beagle 3.1, Beagle 4.1 
and the original SNPTools method. We ran all four methods on five randomly 
selected 1024 site chunks from chromosome 20 on the cluster using increasing 
sample sizes and measured run time. Supplementary Figure 6 shows that 
GLPhase is approximately 100 times faster than the next quickest method at the 
full HRC sample size. 
 
Final phasing and haplotype estimation 
We estimated haplotypes from GLPhase genotype calls using SHAPEIT3
12
. 
Chromosomes were phased in chunks consisting of 16,000 variants plus 3,300 
variants overlapping with neighboring chunks on either side.  The non-default 
command line option -w 0.5 was used for SHAPEIT3.  Chunks were ligated using 
the ligateHAPLOTYPES program (see URLs). SHAPEIT3 does not handle multiple 
variants at the same genomic coordinate, so multiallelic sites (SNPs with 3 or 4 
alleles) were shifted by one or two base pairs for rephasing, and then moved 
back to their original position after chunk ligation. 
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Evaluation of genotype calling process 
We tested the genotype calling process on data from chromosome 20 with 
different combinations of site lists and sample sets to assess both the effects of 
site filtering and the benefits of increasing samples size. We evaluated 3 different 
site lists: the 1000 Genomes Phase 3 set of sites (775,927), our HRC MAC5 site 
list (1,128,114) and our HRC MAC5 site list with additional site filtering 
(1,006,559). We ran the genotype calling method on 3 different sets of samples : 
the 2,525 original 1000 Genomes Phase 3 samples, a subset of 13,309 HRC 
samples that we used at an early stage of HRC testing (HRC Pilot) from studies 
1000GP3, AMD, GoNL, GoT2D, ORCADES, SardinIA, FINLAND and UK10K, and the 
near-final full set of 32,905 HRC samples. We called genotypes using GLPhase on 
each of these 9 datasets and examined genotype discordance compared to 
Illumina OMNI2.5M genotypes produced by the 1000 Genomes Project. For this 
comparison, we focused only on genotypes from 365 samples shared across the 
3 sample sets and at 42,244 SNP sites. We calculated percentage discordance for 
the 3 possible genotypes consisting of reference (REF) and alternate (ALT) 
alleles as well as an overall non-reference allele discordance rate (NRD). Results 
are shown in Supplementary Table 2. 
 
Downstream imputation performance 
We assessed imputation accuracy of 4 different reference panels : 1000 Genomes 
Phase 3, UK10K, and two versions of the HRC reference panel, with and without 
re-phasing with SHAPEIT3. To do this we used high-coverage WGS data made 
publicly available by Complete Genomics (CG) (see URLs). For the pseudo-GWAS 
samples we used data from 10 CEU samples that also occur in the 1000 Genomes 
Phase 3 samples. These samples were removed from the various reference 
panels before using them to assess imputation performance.  
Three pseudo-GWAS panels were created based on three chip lists (see URLs) : 
The Illumina Omni 5M SNP array (HumanOmni5-4v1-1_A), the Illumina Omni 1M 
SNP array (Human1M-Duo v3C), and the Illumina Core Exome SNP array 
(humancoreexome-12v1-1_a). For these comparisons we only used sites in the 
intersection of the reference panels to enable a direct comparison. 
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These pseudo-chip genotypes were used to impute the remaining genotypes 
which were then compared to the held out genotypes, stratifying results by MAF 
of the imputed sites. 
Imputation was carried out using IMPUTE2
7
 
which chooses a custom reference 
panel for each study individual in each 2 Mb segment of the genome. We set the 
k
hap 
parameter of IMPUTE2 to 1000. All other parameters were set to default 
values. We stratified imputed variants into allele frequency bins and calculated 
the squared correlation between the imputed allele dosages at variants in each 
bin with the masked CG genotypes (called aggregate r
2
 in Figure 1). Non-
reference allele frequency for each SNP was calculated from HRC release 1 GLs at 
MAC>=5 sites. Figure 1 shows the results for the Illumina Omni 1M chip. 
Supplementary Figures 3 and 4 show the results from the Illumina Core Exome 
chip and the Illumina Omni 5M chip respectively. 
Details of imputation, association testing and replication in the InCHIANTI study 
A total of 1,210 individuals from the InCHIANTI study were genotyped using the 
Illumina Infinium HumanHap550 genotyping array
13,14
 . Individuals were pre-
phased using autosomal SNPs after filtering out SNPs with MAF <1%, Hardy-
Weinberg p-value <10
-04
, and missingness >1%. SNPs were also removed if they 
could not be remapped to the GRCh37 (hg19) human reference. This resulted in 
483,991 SNPs available for pre-phasing. Phasing was performed locally using 
SHAPEIT2 
10
.  
 
Imputation was performed remotely using the Michigan Imputation Server (see 
URLs). A total of 39,235,157 SNPs and 47,045,346 variants were imputed from 
the HRC and 1000 Genomes Phase 3 (v5) reference panels, respectively. An 
imputation quality threshold of r
2
 >0.5 was subsequently applied to both 
imputation datasets prior to association testing. This resulted in 15,501,516 and 
13,589,949 variants available for association analysis derived from HRC- and 
1000 Genomes-based imputation, respectively. 
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A total of 93 circulating factors available in the InCHIANTI study were double 
inverse-normalised, while adjusted for age and sex, prior to association testing 
14,15
. Association analysis was performed using a linear mixed model framework 
as implemented in GEMMA (see URLs). Plots of association in Figure 2 were 
produced using LocusZoom (see URLs). 
 
We attempted to replicate the associations reported in Supplementary Table 3 in 
the SHIP and SHIP-TREND cohorts
23
. The SHIP samples were genotyped using 
the Affymetrix Genome-Wide Human SNP Array 6.0. The SHIP-TREND samples 
was genotyped using the Illumina Human Omni 2.5 array. Prior to imputation, 
duplicate samples (by IBS), samples with reported vs. genotyped gender 
mismatch or samples with a very high heterozygosity rate were excluded. 
Additionally, all monomorphic SNPs, SNPs with duplicate chromosomal position, 
SNPs with pHWE <0.0001 and SNPs with a callrate <95% were filtered. 
Imputation was performed on the Sanger Imputation Service (see URLs) against 
the HRC panel. In total, 4,070 SHIP samples and 986 SHIP-TREND samples were 
included in the imputation of genotypes. Association analyses were conducted 
using SNPTEST v2.5.2
24
. 
 
 
URLs 
 
Haplotype Reference Consortium 
http://www.haplotype-reference-consortium.org/ 
Michigan Imputation Server 
https://imputationserver.sph.umich.edu/  
Sanger Imputation Server 
https://imputation.sanger.ac.uk/ 
Oxford Phasing Server 
https://phasingserver.stats.ox.ac.uk/ 
Genotype Likelihood calculation scripts 
https://github.com/mcshane/hrc-release1 
GLPhase 
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http://www.stats.ox.ac.uk/~marchini/software/gwas/gwas.html 
ligateHAPLOTYPES 
https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html 
Complete Genomics high-coverage WGS genotypes 
http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/working/20130524_cgi_c
ombined_calls/ 
1000 Genomes Project OMNI genotypes 
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/supporting/hd_ge
notype_chip/ALL.chip.omni_broad_sanger_combined.20140818.snps.genotypes.
vcf.gz 
100,000 Genomes Project 
http://www.genomicsengland.co.uk/the-100000-genomes-project/ 
GEMMA 
http://www.xzlab.org/software.html 
LocusZoom 
http://locuszoom.sph.umich.edu/locuszoom/ 
1000GP3 related samples 
ftp://ftp.1000genomes.ebi.ac.uk//vol1/ftp/release/20130502/20140625_relat
ed_individuals.txt 
SNP chip site lists 
http://www.well.ox.ac.uk/~wrayner/strand/ 
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Figure Legends 
 
Figure 1: Performance of imputation using different reference panel. The x-
axis shows the non-reference allele frequency of the SNP being imputed on a log 
scale. The y-axis shows imputation accuracy measured by aggregate r
2
 when 
imputing SNP genotypes into 10 CEU samples. These results are based on using 
genotypes from sites on Illumina OMNI 1M SNP array was used as pseudo-GWAS 
data. 
 
 
Figure 2 : Association signal  
 
-antitripsin phenotype at the SERPINA1 
locus. Association test statistics on the –log10 p-value scale (y-axis) are plotted 
for each SNP position (x-axis). Three different imputation panels were used : 
HapMap2 (left), 1000GP3 (middle), HRC release 1 (right). The SNP rs28929474  
is shown as a purple and other SNPs are coloured according to the levels of LD 
(r
2
) with this SNP (see r
2 
legend in each subplot). 
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